1   Included studies 1) examined patients with nonulcer dyspepsia and H. pylori infection; 2) used comb

2 t of age- and sex-matched duodenal ulcer and nonulcer dyspepsia patients (16 each).

3 The odds ratio (OR) for treatment success in nonulcer dyspepsia with H. pylori eradication therapy co

4 ptoms shown not to be associated with ulcer (nonulcer dyspepsia) do not now provide an indication for

5  smoking status; diagnosis (ulcer disease or nonulcer dyspepsia); resistance to clarithromycin, imida

6 astric corpus biopsies from 60 patients with nonulcer dyspepsia, and results were correlated with the

7 pylori eradication in infected patients with nonulcer dyspepsia, despite a number of negative efficac

8  we therefore conclude that in patients with nonulcer dyspepsia, H. pylori carriage is associated wit

9                                           In nonulcer dyspepsia, numerous RCTs have yielded conflicti

10                             In patients with nonulcer dyspepsia, the financial benefits of initial an

11 r than from patients with gastritis alone or nonulcer dyspepsia.

12  pylori eradication therapy in patients with nonulcer dyspepsia.

13  end of therapy; and 5) assessed symptoms of nonulcer dyspepsia.

14 ric Rome criteria is allowing recognition of nonulcer (or functional) dyspepsia as an entity that aff

15                  BoNT-A is more effective in nonulcer-type patients.